C

Celltrion Pharm Inc
KOSDAQ:068760

Watchlist Manager
Celltrion Pharm Inc
KOSDAQ:068760
Watchlist
Price: 70 000 KRW Market Closed
Market Cap: ₩3.1T

Net Margin

7%
Current
Improving
by 1.3%
vs 3-y average of 5.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
7%
=
Net Income
₩36.1B
/
Revenue
₩517.6B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
7%
=
Net Income
₩36.1B
/
Revenue
₩517.6B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Celltrion Pharm Inc
KOSDAQ:068760
3.1T KRW
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
571.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
286B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
299.8B USD
Loading...
CH
Novartis AG
SIX:NOVN
226.6B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
213.9B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
154.1B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
122.8B USD
Loading...

Market Distribution

Higher than 74% of companies in Korea
Percentile
74rd
Based on 2 632 companies
74rd percentile
7%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Celltrion Pharm Inc
Glance View

Market Cap
3.1T KRW
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.

Celltrion Pharm Inc Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
7%
=
Net Income
₩36.1B
/
Revenue
₩517.6B
What is Celltrion Pharm Inc's current Net Margin?

The current Net Margin for Celltrion Pharm Inc is 7%, which is above its 3-year median of 5.7%.

How has Net Margin changed over time?

Over the last 3 years, Celltrion Pharm Inc’s Net Margin has increased from 5.9% to 7%. During this period, it reached a low of 2.9% on Jun 30, 2024 and a high of 8% on Jun 30, 2023.

Back to Top